| [1] |
Koay SY, Johnson M, Xing W, et al. Childhood uveitis not associated with juvenile idiopathic arthritis: a national survey of incidence, management and visual outcomes[J]. Eye, 2021, 35(9): 2573－2578.
|
| [2] |
Alexander M, Luo Y, Raimondi G, et al. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune－Mediated Pathologies[J]Pharmaceuticals (Basel), 2021, 15(1): 48.
|
| [3] |
Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis[J]Ocul Immunol Inflamm, 2019, 27(8): 1232－1234.
|
| [4] |
Wennink RAW, de Boer JH, Hiddingh S, et al. Next－Generation HLA Sequence Analysis Uncovers Shared Risk Alleles Between Clinically Distinct Forms of Childhood Uveitis[J]. Invest Ophthalmol Vis Sci, 2021, 62(9): 19.
|
| [5] |
Takeuchi M, Mizuki N, Ohno S. Pathogenesis of non－infectious uveitis elucidated by recent genetic findings[J]. Front Immunol, 2021, 12: 640473.
|
| [6] |
Yan JB, Luo MM. The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease[J]. 2020: 8813558.
|
| [7] |
Sen ES, Ramanan A. Juvenile idiopathic arthritis－associated uveitis[J]. Clinical Immunology, 2020, 211: 108322.
|
| [8] |
Haasnoot AMJ, Kuiper JJ, de Boer JH. Predicting uveitis in juvenile idiopathic arthritis: from biomarkers to clinical practice[J]. Expert Rev Clin Immunol, 2019, 15(6): 657－666.
|
| [9] |
Berkun Y, Bendersky A, Gerstein M, et al. GammadeltaT cells in juvenile idiopathic arthritis: higher percentages of synovial Vdelta1+ and Vgamma9+ T cell subsets are associated with milder disease[J]. J Rheumatol, 2011, 38(6): 1123－1129.
|
| [10] |
Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis[J]. Exp Eye Res, 2007, 85(4): 443－449.
|
| [11] |
Stark GR, Darnell JE. The JAK－STAT pathway at twenty[J]. Immunity, 2012, 36(4): 503－514.
|
| [12] |
Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs[J]. Immunity, 2012, 36(4): 515－528.
|
| [13] |
Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis－associated uveitis[J]. Clin Rheumatol, 2020, 39(3): 847－851.
|
| [14] |
Galvez－Llompart M, Ocello R, Rullo L, et al. Targeting the JAK/STAT Pathway: A Combined Ligand－and Target－Based Approach[J]. J Chem Inf Model, 2021, 61(6): 3091－3108.
|
| [15] |
Darnell JE, Kerr IM, Stark GR. Jak－STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994, 264(5164): 1415－1421.
|
| [16] |
Malki A, ElRuz RA, Gupta I, et al. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements[J]. International journal of molecular sciences, 2020, 22(1): 130.
|
| [17] |
Russell T, Bridgewood C, Rowe H, et al. Cytokine " fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL－17 targeted therapies[J]. Semin Immunopathol, 2021, 43(2): 193－206.
|
| [18] |
Rivellese F, Lobasso A, Barbieri L, et al. Novel therapeutic approaches in rheumatoid arthritis: role of Janus kinases inhibitors[J]. Current Medicinal Chemistry, 2019, 26(16): 2823－2843.
|
| [19] |
Klein K, Stoiber D, Sexl V, et al. Untwining anti－tumor and immunosuppressive effects of JAK inhibitors－a strategy for hematological malignancies？[J]. Cancers, 2021, 13(11): 2611.
|
| [20] |
Hu X, Fu M, Zhao X, et al. The JAK/STAT signaling pathway: From bench to clinic[J]. Signal transduction and targeted therapy, 2021, 6(1): 1－33.
|
| [21] |
Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice[J]. Rheumatology, 2019, 58(Sup1): i4－i16.
|
| [22] |
Virtanen A, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases[J]. BioDrugs, 2019, 33(1): 15－32.
|
| [23] |
Yao N, Tretter T, Kvacskay P, et al. Targeting of Janus Kinases Limits Pro－Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes[J]. Biomedicines, 2021, 9(10): 1413.
|
| [24] |
Karadeniz H, Güler AA, Atas N, et al. Tofacitinib for the treatment for colchicine－resistant familial Mediterranean fever: case－based review[J]. Rheumatology international, 2020, 40(1): 169－173.
|
| [25] |
Bonelli M, Dalwigk K, Platzer A, et al. IRF1 is critical for the TNF－driven interferon response in rheumatoid fibroblast－like synoviocytes[J]. Int J Mol Sci, 2019, 51(7): 1－11.
|
| [26] |
Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how？[J]. Blood, 2014, 124(24): 3529－3537.
|
| [27] |
Verstovsek S, Passamonti F, Rambaldi A, et al. Long－Term Results from a Phase II Open－Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea[J]. Blood, 2014, 124(21): 1847－1847.
|
| [28] |
MacFarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis[J]．Int J Rheum Dis, 2014, 17(4): 359－368.
|
| [29] |
Wenzel J, van Holt N, Maier J, et al. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus[J]. J Investig Dermatol, 2016, 136(6): 1281－1283.
|
| [30] |
Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib[J]. The New England journal of medicine, 2014, 371(26): 2537－2538.
|
| [31] |
Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition[J]. Nature medicine, 2014, 20(9): 1043－1049.
|
| [32] |
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP－690，550)[J]. J Immunol, 2011, 186(7): 4234－4243.
|
| [33] |
O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK－STAT pathway: impact on human disease and therapeutic intervention[J]. Annu Rev Med, 2015, 66: 311－328.
|
| [34] |
ClinicalTrials.gov. Various Jak inhibitor clinical trials (US) 2016[EB/OL]．[2016－12－21].
URL
|
| [35] |
Fleischmann R, Kremer J, Cush J, et al. Placebo－controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med, 2012, 367(6): 495－507.
|
| [36] |
Ruperto N, Brunner HI, Zuber Z, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open－label, multicenter study[J]. Pediatr Rheumatol Online J, 2017, 15(1): 86.
|
| [37] |
Li J. JAK－STAT and bone metabolism[J]. Jak－stat, 2013, 2(3): e23930.
|
| [38] |
Mullard A. FDA approves Eli Lilly′s baricitinib[J]. Nat Rev Drug Discov, 2018, 17(7): 460.
|
| [39] |
Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus——Authors′ reply[J]. Lancet (London, England), 2019, 393(10170): 402－403.
|
| [40] |
Guttman－Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate－to－severe atopic dermatitis: A phase 2 parallel, double－blinded, randomized placebo－controlled multiple－dose study[J]. J Am Acad Dermatol, 2019, 80(4): 913－921.
|
| [41] |
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase Ⅲ，Double－Blind, Randomized Controlled Trial[J]. Arthritis Rheumatol, 2019, 71(11): 1788－1800.
|
| [42] |
Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease[J]. Nat Rev Rheumatol, 2017, 13(4): 234－243.
|
| [43] |
Winthrop KL, Korman N, Abramovits W, et al. T－cell－mediated immune response to pneumococcal conjugate vaccine (PCV－13) and tetanus toxoid vaccine in patients with moderate－to－severe psoriasis during tofacitinib treatment[J]. J Am Acad Dermatol, 2018, 78(6): 1149－1155.
|
| [44] |
González Vicent M, Molina B, González de Pablo J, et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results[J]. American journal of hematology, 2019, 94(3): 319－326.
|
| [45] |
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents[J]. J Am Acad Dermatol, 2017, 76(1): 29－32.
|
| [46] |
Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies[J]. J Clin Invest, 2018, 128(7): 3041－3052.
|
| [47] |
Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster[J]. Therapeutic Advances in Musculoskeletal Disease, 2020, 12: 1759720X20936059.
|
| [48] |
Potera J, Kambhatla S, Gauto－Mariotti E, et al. Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis[J]. Clinical rheumatology, 2021, 40(12): 4845－4851.
|
| [49] |
Strand V, Ahadieh S, French J, et al. Systematic review and meta－analysis of serious infections with tofacitinib and biologic disease－modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials[J]. Arthritis Res Ther, 2015, 17: 362.
|
| [50] |
Lee YH, Song GG. Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta－analysis of randomised controlled trials[J]. Annals of the rheumatic diseases, 2020, 79(10): e122－e122.
|
| [51] |
Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis[J]. Arthritis Rheumatol (Hoboken, NJ), 2019, 71(7): 1042－1055.
|
| [52] |
Sandborn WJ, Panés J. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme[J]. 2019, 50(10): 1068－1076.
|
| [53] |
Gladman DD, Coates LC, Wu J, et al. Time to response for clinical and patient－reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo[J]. Arthritis Res Ther, 2022, 24(1): 1－12.
|